2HIT-Medulloblastoma Oncology Active
New therapy for pediatric patients with group 3 medulloblastoma (MB G3)
Oncoheroes Biosciences’ first drug discovery project aims to develop a more effective and less toxic therapy for medulloblastoma (MB), the most prevalent brain tumor and one of the most aggressive in children. Among the subtypes, Group 3 MB has the worst prognosis, especially if it is associated with MYC gene amplification, with only 20% of patients surviving 5 years after diagnosis.
Eva Mendez
Project Manager
ONCOHEROES BIOSCIENCES. With the collaboration of: IQS · Xenopat · Nostrum Biodiscovery · National Foundation For Cancer Research
Related Projects
Active
Infectious
Interactive game to perform respiratory rehabilitation exercises at home
Enrique del Campo
Active
Orthopedics / Rehabilitation
Six Minute Walk Test Plus (6MWT +) integrates biomechanical sensors into standard exercise
Julita Medina & Arnau Valls
Active
Organizational Innovation
Long-lasting central venous access shield
Jordi Torralba & Montserrat Selvas
